Form 4: UTHR COO Sells Shares Under Pre-Arranged 10b5-1 Plan

United Therapeutics COO Michael Benkowitz sold shares acquired through option exercises under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Michael Benkowitz, President and COO of United Therapeutics Corp (UTHR), reported transactions on February 9, 2026, involving the exercise of stock options and the subsequent sale of the resulting common stock.
• These transactions were executed under a Rule 10b5-1 trading plan established on June 3, 2025.
• From a trust beneficially owned by Benkowitz and his spouse, 14,625 shares were acquired at an exercise price of $117.76 and then sold at $474.6527 per share.
• From a trust beneficially owned by Benkowitz's family members, 7,875 shares were acquired at an exercise price of $146.03 and then sold at $474.6527 per share.
• Following these transactions, Benkowitz directly owns 2,648 shares of common stock.
• He also indirectly holds 24,000 derivative securities (options) via the first trust and 12,940 derivative securities (options) via the second trust.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine, pre-planned insider transaction for liquidity and diversification purposes, which is generally neutral but slightly positive due to the transparency provided by the 10b5-1 plan and the officer's ability to monetize significant value.

Positives

• The officer successfully monetized a significant portion of his stock options at a high market price of $474.6527 per share, indicating substantial personal gain.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which enhances transparency and mitigates concerns about opportunistic insider trading.

Negatives

• The sale of shares by a high-ranking executive, even if pre-planned, could be perceived by some investors as a lack of confidence, although the 10b5-1 plan largely addresses this.

Risks

• No specific risks to the company's operations or financial health are disclosed in this Form 4 filing. The risks are primarily related to the perception of insider sales.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future performance. It solely reports past insider transactions.

Management Comments

• The exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025.

Industry Context

StockSavvy.ai notes that the use of Rule 10b5-1 trading plans is a standard practice among corporate executives in the pharmaceutical and biotechnology sectors, including companies like United Therapeutics, to manage personal liquidity and diversification needs while adhering to insider trading regulations. These plans allow executives to pre-schedule sales of company stock at a time when they are not in possession of material non-public information, thereby providing a legal defense against insider trading claims.

Comparison to Industry Standards

• The execution of stock option exercises and subsequent sales via a Rule 10b5-1 plan is a common and accepted practice for executive compensation and personal financial management across publicly traded companies.
• This aligns with typical executive compensation structures that include equity incentives, similar to practices observed in peer biotech companies such as Gilead Sciences or Amgen.

Corporate Governance

Related Party Transactions

• The transactions involved shares held in trusts where the reporting person and/or his family members are beneficiaries, and the reporting person has shared or sole investment and voting power.

Stakeholder Impact

• Shareholders: Provides transparency regarding executive stock sales, which were pre-planned and not indicative of a sudden change in company outlook.

Next Steps

• The reporting person continues to hold 2,648 shares directly and 36,940 derivative securities (options) indirectly, which may be exercised or sold in the future according to their terms or further 10b5-1 plans.

Key Dates

Recommendation

This Form 4 filing details a pre-scheduled insider sale under a 10b5-1 plan, which is a routine event for executive compensation and personal financial management. It does not provide new material information about United Therapeutics' operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The transaction reflects the officer's personal financial planning rather than a signal about the company's future prospects.

Keywords

United Therapeutics, UTHR, Form 4, insider trading, stock options, 10b5-1 plan, Michael Benkowitz, beneficial ownership